Botox Research Today is a free monthly online journal that collates and summarizes the latest research about Botox, including details on cosmetic botox, side-effects, alternatives, treatment.

A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy.

Carruthers A, Carruthers J

Department of Dermatology and Skin Science, University of British Columbia, 943 W Broadway, Suite 820, Vancouver, British Columbia V5Z 4E1, Canada. alastair@carruthers.net

BACKGROUND: Treating multiple upper facial rhytids at one time is common, but has not been researched extensively. OBJECTIVE: We sought to compare the safety, efficacy, and effect duration of 3 botulinum neurotoxin type A (BoNTA) doses in treating multiple upper facial rhytids. METHOD: Sixty women, randomized to 32, 64, or 96 U total doses, were assessed at baseline, week 2, week 4, then every 4 weeks. The primary efficacy measure was proportion of responders on the patient global assessment of improvement. Adverse events (AEs) were monitored. RESULTS: All BoNTA doses were effective and safe. Significant between-group differences occurred in the percentage of responders (96 U: 71%, 64 U: 61%, 32 U: 26%; P = .0007). Adverse events did not differ significantly among groups; no serious treatment-related adverse events occurred. LIMITATIONS: BoNTA doses were fixed and not tailored to individuals. CONCLUSION: These results confirm the efficacy and safety of 3 doses of BoNTA for treating upper facial rhytids in female patients; higher doses afforded greater benefit.

Published 26 May 2009 in J Am Acad Dermatol, 60(6): 972-9.
Full-text of this article is available online (may require subscription).

© 2004-2010 Botox Research Today. All Rights Reserved.